Variant serum beta-hexosaminidase as a biochemical marker of malignancy.
Variant serum beta-hexosaminidase as a biochemical marker of malignancy.
复制标题
血清β-己糖胺酶变体作为恶性肿瘤的生化标志物。
DOI：
10.1002/1097-0142(19861001)58:7
复制
发表时间：
1986
期刊：
影响因子：
6.2
通讯作者：
Alhadeff,JA
中科院分区：
文献类型：
--
作者：
Plucinsky,MC;Prorok,JJ;Alhadeff,JA
先前的研究已经证明了人肝转移性肿瘤组织和患有肝转移的癌症患者的血清中β-氨基己糖苷酶的变体形式。目前的研究检查了来自大量异质性癌症患者（原发部位不同，转移累及程度不同）、正常对照和非恶性疾病病理对照的血清中β-氨基己糖苷酶变体的存在。总血清β-氨基己糖苷酶活性水平和β-氨基己糖苷酶B（Hex B）占总活性的百分比的比较显示三组之间无显著差异（P> 0.01）。等电聚焦分析表明，108名癌症患者中有80%的人存在β-氨基己糖苷酶变体，27名病理对照中有37%的人存在β-氨基己糖苷酶变体，18名正常对照中有11%存在β-氨基己糖苷酶变体。基于转移程度对癌症患者亚组的检查显示，随着疾病进展，总血清β-氨基己糖苷酶活性显著增加，血清中存在变体β-氨基己糖苷酶。这些结果表明，血清β-氨基己糖苷酶可能是监测恶性疾病进展的有用标志物。
Previous studies have demonstrated a variant form of β‐hexosaminidase in metastatic tumor tissue of human liver and in sera from cancer patients with liver metastases. The current investigation examined sera for the presence of the variant form of β‐hexosaminidase from a large and heterogeneous group of cancer patients (with different primary sites and differing degrees of metastatic involvement), from normal controls and pathological controls with nonmalignant diseases. Comparison of the total serum β‐hexo‐saminidase activity levels and the percentage of the total activity comprised of β‐hexosaminidase B (Hex B) revealed no significant differences (P> 0.01) between the three groups. Analytical isoelectric focusing indicated that the variant β‐hexosaminidase was present in 80% of 108 cancer patients, 37% of 27 pathological controls and 11% of 18 normal controls. Examination of subgroups of the cancer patients based on the extent of metastasis revealed that there was a significant increase in total serum β‐hexo‐saminidase activity and the presence of variant β‐hexosaminidase in the sera as the disease progressed. These results suggest that serum β‐hexosaminidase may be a useful marker for monitoring the progression of malignant disease.